RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Predicting who will experience symptoms after Lyme disease remains challenging Each year, approximately 27,000 people are diagnosed with Lyme disease. For most, the symptoms disappear after treatment with antibiotics. Unfortunately, 25% of those treated have chronic symptoms, such as fatigue, concentration disorders or pain.
National Immunisation Programme: slightly more cases in 2022, but fewer than before the COVID-19 pandemic In 2022, a slightly higher number of people in the Netherlands contracted diseases covered by the National Immunisation Programme (NIP) compared to 2021. This increase is likely due to the easing of coronavirus measures, such as social distancing.
New Zoonoses Report out now: avian flu most notable outbreak in 2022 Throughout 2022, the Netherlands faced a persistent avian flu outbreak, affecting 76 poultry farms. The virus also infected numerous wild birds and various wild mammals. These findings are presented in the Zoonoses Report, an annual publication issued jointly by RIVM and the Netherlands Food and Consumer Product Safety Authority (NVWA).
Vaccination rate increased, HPV even significantly For the first time in five years, the number of children receiving vaccinations from the National Immunisation Programme has increased slightly.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
Corona crisis has limited impact on infant participation in National Immunisation Programme Nearly all infants in the Netherlands are still participating in the National Immunisation Programme.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.